je.st
news
Tag: merck
Merck to pay $100M in NuvaRing contraceptive settlement
2014-02-08 06:36:42| Biotech - Topix.net
Merck & Co. said on Friday it will pay $100 million to resolve all U.S. product liability lawsuits alleging that it downplayed serious health risks involving its NuvaRing intrauterine contraceptive device.
Tags: pay
settlement
100m
merck
Merck Announces Fourth-Quarter and Full-Year 2013 Financial Results
2014-02-05 13:00:00| Merck.com - Corporate News
Dateline City: WHITEHOUSE STATION, N.J. Fourth-Quarter 2013 Non-GAAP EPS Increased by 6 Percent Over Prior Year to $0.88, Excluding Certain Items; GAAP EPS Decreased by 13 Percent to $0.26. Full-Year 2013 Non-GAAP EPS of $3.49, Excluding Certain Items; GAAP EPS of $1.47. Fourth-Quarter 2013 Worldwide Sales Were $11.3 Billion, a Decrease of 4 Percent Reflecting Unfavorable Impact of Patent Expiries and a 3 Percent Negative Impact from Foreign Exchange. Full-Year 2013 Worldwide Sales Were $44.0 Billion, a Decrease of 7 Percent Reflecting Unfavorable Impact of Patent Expiries and a 2 Percent Negative Impact from Foreign Exchange. Strong Full-Year Sales Growth for GARDASIL, REMICADE, SIMPONI, ISENTRESS, ZOSTAVAX and the Diabetes Franchise. Returned $11 Billion to Shareholders in 2013 Through Dividends and Share Repurchases. Accelerated Development Program for MK-3475, Including Announcement of Four Collaborations to Evaluate Novel Combination Regimens, Initiation of a Phase I Study in 20 New Cancer Types and Rolling Submission of a BLA to the FDA. 2014 Full-Year Non-GAAP EPS Target of $3.35 to $3.53, Excluding Certain Items; GAAP EPS Range of $2.15 to $2.47. WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced financial results for the fourth quarter and full year of 2013. Language: English Contact: MerckMedia:Kelley Dougherty, 908- 423-4291Steve Cragle, 908-423-3461orInvestors:Carol Ferguson, 908-423-4465Joe Romanelli, 908-423-5185 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: results
financial
announces
merck
Merck Enters Strategic Collaborations with Amgen, Incyte and Pfizer to Evaluate Novel Combination Anti-cancer Regimens with MK-3475
2014-02-05 12:40:00| Merck.com - Research & Development News
Dateline City: WHITEHOUSE STATION, N.J. Merck Also to Initiate Phase I Signal Finding Study with MK-3475 in 20 New Cancer Types WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today it has signed three separate clinical collaboration agreements, through subsidiaries, with Amgen Inc., Incyte Corporation and Pfizer Inc. to evaluate novel combination regimens with MK-3475, Mercks investigational anti-PD-1 immunotherapy. The financial terms of the agreements were not disclosed. Language: English Contact: MerckMedia:Ian McConnell, 908-423-3046orClaire Mulhearn, 908-423-7425orInvestors:Carol Ferguson, 908-423-4465orJustin Holko, 908-423-5088 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: with
combination
strategic
evaluate
Ablynx agrees Merck cancer deal worth up to 1.7 billion euros
2014-02-04 08:05:11| Biotech - Topix.net
Belgian biotech company Ablynx has signed a deal with Merck & Co worth up to 1.7 billion euros to develop ways of triggering the body to fight cancer by itself.
Canada approves Merck grass allergy immunotherapy
2014-02-03 23:56:05| Biotech - Topix.net
Merck & Co. says it's won its first approval for its new immunotherapy tablet for grass allergies, from regulators in Canada.
Tags: canada
grass
allergy
approves
Sites : [90] [91] [92] [93] [94] [95] [96] [97] [98] [99] [100] [101] [102] [103] [104] [105] [106] [107] [108] [109] next »